Traders Purchase High Volume of Call Options on Teladoc Health (NYSE:TDOC)

Key Points

• Teladoc saw unusually heavy call-option activity: Investors purchased 13,849 call options, roughly 99% above the average volume of 6,959 contracts.
• Shares rose 1.3% to $6.00, but Teladoc remains unprofitable and reported a 4% year-over-year revenue decline in its latest quarter. The company guided to continued losses for Q3 and full-year 2026.
• Analyst sentiment is mixed, with a consensus “Hold” rating and a $7.54 price target; institutional investors own 76.82% of the stock, while the CEO recently sold shares to cover tax withholding obligations.

Teladoc Health, Inc. (NYSE:TDOC - Get Free Report) saw unusually large options trading on Tuesday. Investors purchased 13,849 call options on the stock. This is an increase of approximately 99% compared to the average volume of 6,959 call options.

Teladoc Health Trading Up 1.3%

Shares of NYSE:TDOC traded up $0.07 during trading on Tuesday, reaching $6.00. The stock had a trading volume of 2,975,497 shares, compared to its average volume of 5,091,613. Teladoc Health has a one year low of $4.40 and a one year high of $9.89. The company has a market capitalization of $1.09 billion, a P/E ratio of -6.06 and a beta of 2.14. The firm's 50-day simple moving average is $6.30 and its 200 day simple moving average is $6.87.

Teladoc Health (NYSE:TDOC - Get Free Report) last issued its quarterly earnings data on Wednesday, July 29th. The health services provider reported ($0.21) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.25) by $0.04. The firm had revenue of $606.93 million for the quarter, compared to the consensus estimate of $615.44 million. Teladoc Health had a negative net margin of 7.13% and a negative return on equity of 12.15%. The company's quarterly revenue was down 4.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.19) EPS. Teladoc Health has set its Q3 2026 guidance at -0.300--0.200 EPS and its FY 2026 guidance at -1.000--0.750 EPS. Equities research analysts forecast that Teladoc Health will post -0.92 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. Citigroup dropped their target price on shares of Teladoc Health from $11.00 to $7.50 and set a "neutral" rating on the stock in a report on Monday, August 3rd. Bank of America boosted their price target on shares of Teladoc Health from $9.00 to $10.50 and gave the company a "buy" rating in a report on Tuesday, July 7th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Teladoc Health in a research report on Wednesday, August 19th. Finally, Canaccord Genuity Group lowered their price target on shares of Teladoc Health from $11.00 to $10.00 and set a "buy" rating for the company in a research report on Thursday, July 30th. Five research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Teladoc Health has a consensus rating of "Hold" and a consensus price target of $7.54.

Insider Buying and Selling at Teladoc Health

In other news, CEO Charles III sold 17,805 shares of the stock in a transaction on Friday, September 11th. The stock was sold at an average price of $6.10, for a total transaction of $108,610.50. Following the transaction, the chief executive officer owned 465,535 shares of the company's stock, valued at approximately $2,839,763.50. This represents a 3.68% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 0.70% of the company's stock.

Hedge Funds Weigh In On Teladoc Health

A number of large investors have recently made changes to their positions in TDOC. ABS Direct Equity Fund LLC purchased a new stake in shares of Teladoc Health during the 2nd quarter valued at $1,513,000. WINTON GROUP Ltd grew its stake in Teladoc Health by 402.4% during the 2nd quarter. WINTON GROUP Ltd now owns 227,100 shares of the health services provider's stock worth $1,926,000 after buying an additional 181,900 shares during the last quarter. Nykredit A S acquired a new position in Teladoc Health during the 2nd quarter valued at about $27,000. HighTower Advisors LLC increased its position in Teladoc Health by 20.8% during the 2nd quarter. HighTower Advisors LLC now owns 16,808 shares of the health services provider's stock valued at $143,000 after buying an additional 2,893 shares in the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in Teladoc Health during the 2nd quarter valued at about $1,447,000. 76.82% of the stock is owned by institutional investors and hedge funds.

About Teladoc Health

Teladoc Health, Inc NYSE: TDOC provides virtual healthcare services and technology that connect patients with physicians, therapists and other healthcare professionals. Its platform supports general medical care, specialist consultations, mental health services, chronic condition management and related healthcare programs through digital and remote-care channels.

The company's offerings include Teladoc's telehealth services, BetterHelp's online counseling and therapy platform, and chronic care solutions developed through Livongo, which Teladoc acquired in 2020.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.